Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
|Articles|April 12, 2012
Blazing a Trail: Pioneer ACOs Test Strategies with Five Pay Options
Advertisement
Physicians at Beth Israel Deaconess Medical Center in Boston are among the first to test Medicare accountable care, but they did not go all-in right away.
The Beth Israel Deaconess Physician Organization chose a slow start from among the options offered by federal health officials who are testing five payment models on 32 accountable care organizations that launched in January.
Read the full story:
Source: ModernHealthcare.com
For Beth Israel doctors, that strategy allows some breathing room to adapt for a year before any financial risks kick in, said Roberta Zysman, the physician organization's executive director.
Advertisement
Related to this article
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Preparing Practices for the Next Era of Hepatitis B Care
4
Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
5